Economic burden of antibiotic-not-susceptible isolates in uncomplicated urinary tract infection: Analysis of a US integrated delivery network database

Table 2 Sensitivity analyses summary (uUTI patients with susceptible or not-susceptible isolates)

Sensitivity analysis	Sample size	Difference [not-susceptible − susceptible] (P-value)
		Probability of progressing to cUTI		All-cause costs		UTI-related costs		All-cause costs (winsorized)		UTI-related costs (winsorized)
		Difference	P-value	Difference	P-value	Difference	P-value	Difference	P-value	Difference	P-value
Baseline	1009	+ 0.060	< 0.001*	+ 430.9	0.125	+ 184.3	0.144	+ 425.7	0.031*	+ 156.8	0.034*
#1 (strict exclusion)	661	+ 0.039	0.009*	+ 797.7	0.014*	+ 304.6	0.043*	+ 653.5	0.002*	+ 217.5	0.028*
#2 (30-day follow-up)	1200	+ 0.057	< 0.001*	− 12.85	0.910	+ 17.57	0.877	+ 36.00	0.614	+ 22.65	0.555
#3 (360-day follow-up)	834	+ 0.058	< 0.001*	+ 412.2	0.285	+ 126.7	0.409	+ 301.9	0.256	+ 65.25	0.478
#4 (loose exclusion)	1009	+ 0.060	< 0.001*	+ 430.9	0.125	+ 184.3	0.144	+ 425.7	0.031*	+ 156.8	0.034*
#6 (infectious exclusion)	955	+ 0.058	< 0.001*	+ 511.7	0.060	+ 206.5	0.085	+ 471.7	0.012*	+ 73.15	0.139
#7 (FQs-only)	166	+ 0.036	0.387	+ 605.8	0.316	+ 186.3	0.471	+ 484.9	0.307	+ 196.0	0.369

J Shafrin. Progression of an Uncomplicated Urinary Tract Infection Among Female Patients with Susceptible and Non-Susceptible Urine Isolates: Findings from an Integrated Delivery Network. [Paper/Poster/Talk] presented at IDWeek; September 29–October 3, 2021; Virtual Event. https://idweek.org
^*Statistically significant (P-value < 0.05)
cUTI complicated urinary tract infection; FQ fluoroquinolone; UTI urinary tract infection; uUTI uncomplicated urinary tract infection

ISSN: 2047-2994